Investors

Information for investors including share information, share analysis, shareholder news and annual reports.

GSK plc today announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses

Read more

Q1 2014 results will be announced on Wed 30 April:

Register for the analysts' webcast
View Q1 2014 aide memoire (PDF)

stock prices
Investing in GSK

Reasons to invest in GSK - a global healthcare company enabling people to do more, feel better and live longer.

Corporate reporting

Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.

Press releases

These press releases are intended for business journalists and analysts/investors.
22 April 2014

GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

GlaxoSmithKline plc today announces a major three-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses

22 April 2014

GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing in Japan

GlaxoSmithKline (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate and long-acting beta2 agonist (LABA), vilanterol (FF/VI).

17 April 2014

GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate

GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

UK Map
Investor relations UK
  
GlaxoSmithKline plc
   Tel: 020 8047 5000
980 Great West Road
    Fax: 020 8047 7807
Brentford
Middlesex TW8 9GS

Investor downloads

Our product pipeline      
Our product pipeline 0.3MB